BlossomHill Therapeutics, Inc. (BLSM)
| Market Cap | 548.93M |
| Revenue (ttm) | n/a |
| Net Income | -81.60M |
| EPS | -31.83 |
| Shares Out | 31.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,799 |
| Open | 17.43 |
| Previous Close | 17.27 |
| Day's Range | 17.34 - 18.74 |
| 52-Week Range | 15.25 - 27.99 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.40 (+104.98%) |
| Est. Earnings | Nov 19, 2026 |
About BLSM
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BLSM stock is "Strong Buy." The 12-month stock price target is $35.4, which is an increase of 104.98% from the latest price.
News
BlossomHill Therapeutics presents preclinical data on BH-501284 at AACR
BlossomHill Therapeutics (BLSM) announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research, AACR, Conference on Pancreatic Cancer: New Frontiers in Bio...
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND s...
BlossomHill Therapeutics price target raised to $40 from $36 at Leerink
Leerink raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $36 and keeps an Outperform rating on the shares.
BlossomHill Therapeutics price target raised to $40 from $30 at Guggenheim
Guggenheim raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $30 and keeps a Buy rating on the shares after the company reported Q2 results and provided…
BlossomHill Therapeutics reports Q2 EPS ($8.75) vs ($5.51) last year
“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,” said Jean Cui, Ph.D., Founder, President and Chief...
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-posit...
BlossomHill Therapeutics Earnings release: Q2 2026
BlossomHill Therapeutics released its Q2 2026 earnings on September 18, 2026, summarizing the period's financial results.
BlossomHill Therapeutics Quarterly report: Q2 2026
BlossomHill Therapeutics has published its Q2 2026 quarterly earnings report on September 18, 2026.
BlossomHill Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
BlossomHill presented strong phase I data for its lead EGFR inhibitor, showing high response rates and durability in C797S-resistant patients, with a favorable safety profile and differentiation from competitors. Key milestones include pivotal trial planning and new data readouts through 2027.
BlossomHill Therapeutics announces updated SOLARA trial data
BlossomHill Therapeutics (BLSM) announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancerm or NSCLC, patients with secondary epidermal growth factor rece...
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat popul...
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and ...
Guggenheim starts BlossomHill Therapeutics with a Buy on pipeline potential
As previously reported, Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target BlossomHill’s “precision oncology” pipeline has potential to generate “s...
BlossomHill Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $36 price target
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Tr...
BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $32 price target
BlossomHill Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target
BlossomHill Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Robert Burns initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $35 price target BlossomHill is focused on the design and development of novel, proprie...
BlossomHill Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of BlossomHill Therapeutics (BLSM) with an Overweight rating and $28 price target BlossomHill is a clinical-stage oncology company “leveraging management’s valuable know-ho...
BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA
BlossomHill Therapeutics (BLSM) announced that the FDA has granted fast track designation to BH-30643 for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor C...
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and d...
BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO
Shares in cancer-focused biotech firm BlossomHill Therapeutics ($BLSM) dropped nearly 3% in its stock market debut after it raised $150 million in its U.S. IPO. Below the IPO Price The…
BlossomHill Therapeutics opens at $15.75, IPO priced at $16.00
BlossomHill Therapeutics (BLSM) priced 9.375M shares at $16.00. The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00…
BlossomHill Therapeutics 9.375M share IPO priced at $16.00
The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00 range. JPMorgan, Leerink, Guggenheim, Lake Street and H.C.
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach...